3I TG OSSEOTITE IMPLANT, MODELS TG685, TG610, TG611, TG613, TG5685, TG5610, TG5611, TG5613, TG5615
Device Facts
| Record ID | K033430 |
|---|---|
| Device Name | 3I TG OSSEOTITE IMPLANT, MODELS TG685, TG610, TG611, TG613, TG5685, TG5610, TG5611, TG5613, TG5615 |
| Applicant | Implant Innovations, Inc. |
| Product Code | DZE · Dental |
| Decision Date | Nov 7, 2003 |
| Decision | SESE |
| Submission Type | Special |
| Regulation | 21 CFR 872.3640 |
| Device Class | Class 2 |
Indications for Use
The 3i TG OSSEOTITE® Wide Implants are indicated for surgical placement in the upper or lower jaw to provide a means for prosthetic attachment.
Device Story
3i TG OSSEOTITE® Wide Implants are trans-gingival endosseous dental implants; feature internal morse-taper design; wider seating surface mimics natural tooth proportions in posterior jaw regions. Implants are surgically placed in upper or lower jaw by dental professionals to serve as anchors for prosthetic attachments. Device provides structural foundation for dental restorations; benefits patients by restoring function and aesthetics of missing teeth.
Clinical Evidence
No clinical data provided; substantial equivalence based on design and technological characteristics.
Technological Characteristics
Trans-gingival endosseous dental implant; internal morse-taper connection; wide diameter design for posterior tooth replacement. Materials and manufacturing processes are consistent with predicate TG OSSEOTITE® line.
Indications for Use
Indicated for surgical placement in the upper or lower jaw of patients requiring prosthetic attachment.
Regulatory Classification
Identification
An endosseous dental implant is a prescription device made of a material such as titanium or titanium alloy that is intended to be surgically placed in the bone of the upper or lower jaw arches to provide support for prosthetic devices, such as artificial teeth, in order to restore a patient's chewing function.
Special Controls
*Classification.* (1) Class II (special controls). The device is classified as class II if it is a root-form endosseous dental implant. The root-form endosseous dental implant is characterized by four geometrically distinct types: Basket, screw, solid cylinder, and hollow cylinder. The guidance document entitled “Class II Special Controls Guidance Document: Root-Form Endosseous Dental Implants and Endosseous Dental Implant Abutments” will serve as the special control. (See § 872.1(e) for the availability of this guidance document.)(2) *Classification.* Class II (special controls). The device is classified as class II if it is a blade-form endosseous dental implant. The special controls for this device are:(i) The design characteristics of the device must ensure that the geometry and material composition are consistent with the intended use; (ii) Mechanical performance (fatigue) testing under simulated physiological conditions to demonstrate maximum load (endurance limit) when the device is subjected to compressive and shear loads; (iii) Corrosion testing under simulated physiological conditions to demonstrate corrosion potential of each metal or alloy, couple potential for an assembled dissimilar metal implant system, and corrosion rate for an assembled dissimilar metal implant system; (iv) The device must be demonstrated to be biocompatible; (v) Sterility testing must demonstrate the sterility of the device; (vi) Performance testing to evaluate the compatibility of the device in a magnetic resonance (MR) environment; (vii) Labeling must include a clear description of the technological features, how the device should be used in patients, detailed surgical protocol and restoration procedures, relevant precautions and warnings based on the clinical use of the device, and qualifications and training requirements for device users including technicians and clinicians; (viii) Patient labeling must contain a description of how the device works, how the device is placed, how the patient needs to care for the implant, possible adverse events and how to report any complications; and (ix) Documented clinical experience must demonstrate safe and effective use and capture any adverse events observed during clinical use.